Lilly says Alzheimer's 麻薬 slows 臨床の 拒絶する／低下する in 中央の-行う／開催する／段階 裁判，公判
By Deena Beasley
Jan 11 (Reuters) - Eli Lilly and Co said on Monday a 裁判，公判 of its 実験の Alzheimer's 麻薬 donanemab showed it slowed by about a third the 率 of 拒絶する／低下する in a 連合させるd 手段 of cognition and 機能（する）／行事 in 早期に-行う／開催する／段階 犠牲者s of the 病気.
The 麻薬 is an antibody designed to 除去する clumps of the Alzheimer's-関係のある protein beta amyloid from the brain.
Lilly said the 中央の-行う／開催する／段階 裁判，公判 of 272 患者s met its main goal of showing a statistically 重要な change in 臨床の 拒絶する／低下する over 18 months.
Donanemab 的s a type of beta amyloid known as N3pG which Lilly believes can be 速く （疑いを）晴らすd, enabling short-称する，呼ぶ／期間／用語, but 持続する, 治療.
患者s in the 熟考する／考慮する stopped receiving donanemab and were switched to placebo once their brain plaques reached levels seen in healthy people - a 過程 that took just a few months for some 患者s.
"This 熟考する／考慮する shows that the presence of amyloid is an important accelerant of Alzheimer's 病気," Daniel Skovronsky, Lilly´s 長，指導者 科学の officer, told Reuters.
The results also "tell us that there are other things at play," he 追加するd, 説 付加 戦略s were needed to fully 戦闘 Alzheimer's.
A brain swelling 味方する 影響, known as ARIA-E, occurred in 27% of 患者s 扱う／治療するd with donanemab, the company said.
"Alzheimer's 病気 is uniformly 致命的な ... I think this safety profile matched with this efficacy profile is something that we can be excited about," Skovronsky said.
Lilly said donanemab also showed 肯定的な results in the 裁判，公判's 第２位 endpoints 手段ing cognition and 機能（する）／行事, but did not reach 統計に基づく significance on all of them.
The company is continuing to 熟考する／考慮する the 麻薬 in a second, 500-患者 裁判，公判.
Lilly, along with companies like Biogen Inc and Eisai Co Ltd, is one of the last large drugmakers 追求するing 治療s for Alzheimer's - a 病気 that afflicts nearly 6 million Americans a nd millions more 世界的な.
The U.S. Food and 麻薬 行政 is reviewing Biogen's 使用／適用 for aducanumab, which also 的s amyloid plaques.
Biogen said one of its two pivotal aducanumab 熟考する／考慮するs showed a statistically 重要な 利益 in slowing cognitive and 機能の 拒絶する／低下する, but a second 裁判，公判 行方不明になるd that goal, showing 利益 only for some 患者s who got a high dose for at least 10 months.
Lilly said 十分な 裁判，公判 results would be 現在のd at a 未来 医療の 会合 and submitted for 出版（物） in a peer-reviewed 臨床の 定期刊行物. (報告（する）／憶測ing by Deena Beasley; Editing by Clarence Fernandez)
